Merck has just announced an, as of now, pill-in-development to fight Covid-19. According to an internal Merck study, this pill has cut the risk of hospitalization or death from Covid-19 in half. If approved, this pill would become the first oral medicine to fight the viral infection for Covid-19.
“At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%,” Merck said in a news release. “7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo treated patients (53,377). Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo.”
Merck added that it will seek FDA emergency use authorization “as soon as possible.”